Stanley-Laman Group’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History

Stanley-Laman Group’s Portfolio EGRX Stock Details EGRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$4.09K	Hold	12,000	–	–	﹤0.01%	293
2025 Q4	$8.4K	Hold	12,000	–	–	﹤0.01%	303
2025 Q3	$32.4K	Hold	12,000	–	–	﹤0.01%	250
2025 Q2	$34.8K	Hold	12,000	–	–	0.01%	281
2025 Q1	$11.8K	Hold	12,000	–	–	﹤0.01%	281
2024 Q4	$6K	Hold	12,000	–	–	﹤0.01%	282
2024 Q3	$44.8K	Hold	12,000	–	–	0.01%	289
2024 Q2	$67.2K	Hold	12,000	–	–	0.01%	269
2024 Q1	$62.9K	Hold	12,000	–	–	0.01%	246
2023 Q4	$62.8K	Hold	12,000	–	–	0.01%	230
2023 Q3	$189K	Hold	12,000	–	–	0.03%	229
2023 Q2	$233K	Hold	12,000	–	–	0.04%	215
2023 Q1	$340K	Hold	12,000	–	–	0.06%	190
2022 Q4	$351K	Hold	12,000	–	–	0.07%	175
2022 Q3	$317K	Hold	12,000	–	–	0.06%	183
2022 Q2	$533K	Sell	12,000 -12,000	-50%	-$551K	0.09%	192
2022 Q1	$1.19M	Hold	24,000	–	–	0.16%	166
2021 Q4	$1.22M	Hold	24,000	–	–	0.14%	180
2021 Q3	$1.34M	Hold	24,000	–	–	0.17%	169
2021 Q2	$1.03M	Hold	24,000	–	–	0.15%	184
2021 Q1	$1M	Hold	24,000	–	–	0.17%	175
2020 Q4	$1.12M	Buy	24,000 +12,000	+100%	+$561K	0.2%	160
2020 Q3	$510K	Sell	12,000 -12,000	-50%	-$525K	0.11%	180
2020 Q2	$1.15M	Hold	24,000	–	–	0.28%	98
2020 Q1	$1.1M	Hold	24,000	–	–	0.34%	82
2019 Q4	$1.44M	Hold	24,000	–	–	0.34%	90
2019 Q3	$1.36M	Hold	24,000	–	–	0.34%	89
2019 Q2	$1.34M	Hold	24,000	–	–	0.32%	92
2019 Q1	$1.21M	Hold	24,000	–	–	0.29%	99
2018 Q4	$967K	Hold	24,000	–	–	0.27%	113
2018 Q3	$1.66M	Hold	24,000	–	–	0.41%	81
2018 Q2	$1.82M	Hold	24,000	–	–	0.41%	76
2018 Q1	$1.26M	Hold	24,000	–	–	0.29%	100
2017 Q4	$1.28M	Hold	24,000	–	–	0.28%	99
2017 Q3	$1.43M	Hold	24,000	–	–	0.38%	85
2017 Q2	$1.89M	Hold	24,000	–	–	0.51%	71
2017 Q1	$1.99M	Hold	24,000	–	–	0.54%	55
2016 Q4	$1.9M	Hold	24,000	–	–	0.59%	53
2016 Q3	$1.68M	Hold	24,000	–	–	0.69%	24
2016 Q2	$931K	Hold	24,000	–	–	0.36%	99
2016 Q1	$972K	Hold	24,000	–	–	0.18%	116
2015 Q4	$2.13M	Hold	24,000	–	–	0.36%	88
2015 Q3	$1.78M	Hold	24,000	–	–	0.36%	81
2015 Q2	$1.94M	Hold	24,000	–	–	0.36%	87
2015 Q1	$1M	Sell	24,000 -108,790	-82%	-$3.09M	0.18%	135
2014 Q4	$2.06M	Hold	132,790	–	–	0.39%	82
2014 Q3	$1.68M	Buy	+132,790	New	+$1.65M	0.33%	94

Other funds holding EGRX

AIC

Archer Investment Corporation Carmel, Indiana $469M AUM 19.1% 1-Year Est. Return

Stanley-Laman Group's EGRX Position: Q1 2026 in Review

Stanley-Laman Group held its Eagle Pharmaceuticals, Inc. (EGRX) position steady in Q1 2026 at 12,000 shares worth $4.09K. The position accounts for ﹤0.01% of the portfolio, ranked #293.

Stanley-Laman Group first reported a position in EGRX in Q3 2014 and has held it in 47 quarters since. The position peaked at $2.13M in Q4 2015. 2 funds tracked by Wall St. Rank hold EGRX as of Q1 2026.

Stanley-Laman Group held 12,000 shares of Eagle Pharmaceuticals, Inc. worth $4.09K as of Q1 2026.
Stanley-Laman Group left its Eagle Pharmaceuticals, Inc. share count unchanged in Q1 2026.
Eagle Pharmaceuticals, Inc. made up ﹤0.01% of Stanley-Laman Group's portfolio in Q1 2026, its #293 holding.
Stanley-Laman Group first reported a position in Eagle Pharmaceuticals, Inc. in Q3 2014 and has held it in 47 quarters since.
Stanley-Laman Group's Eagle Pharmaceuticals, Inc. position peaked at $2.13M in Q4 2015.
2 funds tracked by Wall St. Rank held Eagle Pharmaceuticals, Inc. as of Q1 2026.

Based on Stanley-Laman Group's 13F filing for Q1 2026, filed 16 Apr 2026.